Anebulo Pharmaceuticals, Inc. financial statements
Income statement, balance sheet and cash flow statement for the last 5 fiscal years, taken from the XBRL data Anebulo Pharmaceuticals, Inc. files with the SEC in its annual reports.
In USD millions, except per-share amounts. Outflows in the cash flow statement are negative.
Income statement
FY2021
FY2022
FY2023
FY2024
FY2025
Research and development
2.27
2.96
5.6
3.55
4.3
General and administrative
1.34
3.87
6.18
4.76
4.92
Operating expenses
3.61
6.83
11.8
8.31
9.22
Operating income
-3.61
-6.83
-11.8
-8.31
-9.22
Interest expense
0.01
0.2
0.4
Interest income
0
0.01
0.09
0.25
0.26
Other non-operating income
-26.6
0.01
0.05
0.11
0.74
Pre-tax income
-3.61
Net income
-30.3
-6.83
-11.7
-8.2
-8.48
EPS, basic
-2.83
0.29
-0.47
-0.32
-0.25
EPS, diluted
-2.83
0.29
-0.47
-0.32
-0.25
Shares, basic (weighted)
13.6
23.3
25.1
25.8
33.8
Shares, diluted (weighted)
13.6
23.3
25.1
25.8
33.8
Balance sheet
FY2021
FY2022
FY2023
FY2024
FY2025
Cash and equivalents
20
14.5
11.2
3.09
11.6
Other current assets
1.67
1.03
0.42
0.41
0.26
Total current assets
11.7
3.51
12
Other non-current assets
0.57
0.18
Total assets
21.7
15.6
11.7
4.07
12.1
Accounts payable
0.11
0.38
0.53
0.16
0.22
Accrued liabilities
0.13
0.13
0.53
0.1
0.26
Total liabilities
0.24
0.51
1.07
0.26
0.49
Paid-in capital
60
60.5
67.8
69.2
85.5
Retained earnings
-38.6
-45.5
-57.2
-65.4
-73.9
Shareholders' equity
21.4
15.1
10.6
3.81
11.7
Total equity
21.4
15.1
10.6
3.81
11.7
Total liabilities and equity
21.7
15.6
11.7
4.07
12.1
Shares outstanding
23.3
23.3
25.6
25.9
41.1
Cash flow statement
FY2021
FY2022
FY2023
FY2024
FY2025
Net income
-30.3
-6.83
-11.7
-8.2
-8.48
Stock-based compensation
0.2
0.48
0.88
0.76
1.45
Change in payables
0.11
0.27
0.15
-0.38
0.07
Cash from operations
-4.87
-5.44
-9.68
-8.09
-6.35
Stock issued
20.6
6.65
15
Cash from financing
21.8
6.38
-0.06
14.9
Net change in cash
17
-5.44
-3.3
-8.15
8.53
Interest paid
0.01
Key metrics
Worked out from the statements above. Latest values use the trailing twelve months to December 31, 2025; growth uses fiscal years. Valuation uses the share price of $0.33 on September 25, 2026.
Profitability
Metric
Value
How it is calculated
Return on equity (ROE)
-100.5%
Net income / average shareholders' equity (opening and closing). Not shown when equity is negative.
Return on assets (ROA)
-84.7%
Net income / average total assets.
Growth
Metric
Value
How it is calculated
Book value growth, 1y
205.8%
Book value vs the same period a year earlier. Only from a positive base.
Book value CAGR, 3y
-8.2%
Compound annual growth of book value over 3 fiscal years: (end / start)^(1/3) - 1. Only when both values are positive.
Total assets growth, 1y
198.2%
Total assets vs the same period a year earlier. Only from a positive base.
Total assets CAGR, 3y
-8.0%
Compound annual growth of total assets over 3 fiscal years: (end / start)^(1/3) - 1. Only when both values are positive.
Share count change, 1y
31.0%
Change in diluted weighted shares vs a year earlier. Negative means buybacks shrank the share count; positive means dilution.
Share count change per year, 3y
13.2%
Change in diluted weighted shares, per year over 3 years. Negative means buybacks shrank the share count; positive means dilution.
Net income per diluted share, as reported (split-adjusted). Over the last twelve months: the four quarters summed, or net income / latest diluted shares when a quarter has no reported EPS.
Operating cash flow per share
-$0.14
Cash from operations / diluted weighted shares.
Book value per share
$0.19
Shareholders' equity / shares outstanding (diluted weighted shares when not reported).
Market cap + total debt - cash - short-term investments.
P/B
1.67x
Market cap / shareholders' equity. Only when equity is positive.
Price / tangible book
1.67x
Market cap / tangible book value, when positive.
Earnings yield
-60.2%
Net income / market cap (the inverse of P/E).
Was Anebulo Pharmaceuticals, Inc. profitable in fiscal 2025?
No. It reported a net loss of $8.5M.
Source: SEC EDGAR XBRL company facts. Where a company tags only year-to-date figures, quarters are worked out as differences. Where a line is not tagged it is left empty, never estimated.